

Chapter 40

REFERENCES

1. Fisher DM. (Almost) everything you learned about pharmacokinetics was (somewhat) wrong! *Anesth Analg*. 1996;83(5):901-903.
2. Ebling WF, Lee EN, Stanski DR. Understanding pharmacokinetics and pharmacodynamics through computer stimulation: I. The comparative clinical profiles of fentanyl and alfentanil. *Anesthesiology*. 1990;72(4):650-658.
3. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. *Br J Anaesth*. 1991;67(1):41-48.
4. Shafer SL, Stanski DR. Improving the clinical utility of anesthetic drug pharmacokinetics. *Anesthesiology*. 1992;76(3):327-330.
5. Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. *Anesthesiology*. 1992;76(3):334-341.
6. Youngs EJ, Shafer SL. Pharmacokinetic parameters relevant to recovery from opioids. *Anesthesiology*. 1994;81(4):833-842.
7. Boer F, Olofsen E, Bovill JG, et al. Pulmonary uptake of sufentanil during and after constant rate infusion. *Br J Anaesth*. 1996;76(2):203-208.
8. Marsh BJ, Morton NS, White M, Kenny GN. A computer controlled infusion of propofol for induction and maintenance of anaesthesia in children. *Can J Anaesth*. 1990;37(4 Pt 2):S97.
9. Maitre PO, Shafer SL. A simple pocket calculator approach to predict anesthetic drug concentrations from pharmacokinetic data. *Anesthesiology*. 1990;73(2):332-336.
10. Arden JR, Holley FO, Stanski DR. Increased sensitivity to etomidate in the elderly: initial distribution versus altered brain response. *Anesthesiology*. 1986;65(1):19-27.
11. Minto CF, Schnider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. *Anesthesiology*. 1997;86(1):10-23.
12. Wertz E. Does etomidate cause haemolysis? *Br J Anaesth*. 1993;70(4):490-491.
13. Shafer SL. More on pharmacokinetics with a pocket calculator. *Anesthesiology*. 1991;74(3):631.
14. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. *Clin Pharmacol Ther*. 1979;25(3):358-371.
15. Stanski DR, Ham J, Miller RD, Sheiner LB. Pharmacokinetics and pharmacodynamics of d-tubocurarine during nitrous oxide-narcotic and halothane anesthesia in man. *Anesthesiology*. 1979;51(3):235-241.
16. Jacobs JR, Reves JG. Effect site equilibration time is a determinant of induction dose requirement. *Anesth Analg*. 1993;76(1):1-6.
17. Verotta D, Sheiner LB. Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm. *Comput Appl Biosci*. 1987;3(4):345-349.
18. Arrowsmith JB, Gerstman BB, Fleischer DE, Benjamin SB. Results from the American Society for Gastrointestinal Endoscopy/U.S. Food and Drug Administration collaborative study on complication rates and drug use during gastrointestinal endoscopy. *Gastrointest Endosc*. 1991;37(4):421-427.
19. Michalodimitrakis M, Christodoulou P, Tsatsakis AM, et al. Death related to midazolam overdose during endoscopic retrograde cholangiopancreatography. *Am J Forensic Med Pathol*. 1999;20(1):93-97.
20. Levy L, Pandit SK. Is midazolam a dangerous drug? *J Post Anesth Nurs* 1989;4(1):40-43.
21. Babenco HD, Conard PF, Gross JB. The pharmacodynamic effect of a remifentanil bolus on ventilatory control. *Anesthesiology*. 2000;92(2):393-398.
22. Bouillon T, Bruhn J, Radu-Radulescu L, et al. A model of the ventilatory depressant potency of remifentanil in the non-steady state. *Anesthesiology*. 2003;99(4):779-787.
23. Richardson SP, Egan TD. The safety of remifentanil by bolus injection. *Expert Opin Drug Saf*. 2005;4(4):643-651.
24. Egan TD, Shafer SL. Target-controlled infusions for intravenous anesthetics: surfing USA not! *Anesthesiology*. 2003;99(5):1039-1041.
25. Kern SE, Xie G, White JL, Egan TD. A response surface analysis of propofol-remifentanil pharmacodynamic interaction in volunteers. *Anesthesiology*. 2004;100(6):1373-1381.
26. Egan TD, et al. The electroencephalogram (EEG) and clinical measures of opioid potency: defining the EEG-clinical potency relationship ("fingerprint") with application to remifentanil. *Int J Pharm Med*. 2001;15(1):1-8.
27. Ausems ME, Vuyk J, Hug CC Jr, Stanski DR. Comparison of a computer-assisted infusion versus intermittent bolus administration of alfentanil as a supplement to nitrous oxide for lower abdominal surgery. *Anesthesiology*. 1988. 68(6):851-861.
28. Ausems ME, Hug CC Jr, Stanski DR, Burm AG. Plasma concentrations of alfentanil required to supplement nitrous oxide anesthesia for general surgery. *Anesthesiology*. 1986;65(4):362-373.

29. Egan TD, Minto CF, Hermann DJ, et al. Remifentanyl versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. *Anesthesiology*. 1996;84(4):821-833.
30. Ebling WF, Levy G. Population pharmacodynamics: strategies for concentration-and effect-controlled clinical trials. *Ann Pharmacother*. 1996;30(1):12-19.
31. Vuyk J, Mertens MJ, Olofsen E, et al. Propofol anesthesia and rational opioid selection: determination of optimal EC50-EC95 propofol-opioid concentrations that assure adequate anesthesia and a rapid return of consciousness. *Anesthesiology*. 1997;87(6):1549-1562.
32. Schnider TW, Minto CF, Shafer SL, et al. The influence of age on propofol pharmacodynamics. *Anesthesiology*. 1999;90(6):1502-1516.
33. Struys MM, Vereecke H, Moerman A, et al. Ability of the bispectral index, autoregressive modelling with exogenous input-derived auditory evoked potentials, and predicted propofol concentrations to measure patient responsiveness during anesthesia with propofol and remifentanyl. *Anesthesiology*. 2003;99(4):802-812.
34. Mildh LH, Scheinin H, Kirvela OA. The concentration-effect relationship of the respiratory depressant effects of alfentanil and fentanyl. *Anesth Analg*. 2001;93(4):939-946.
35. Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. *Anesthesiology*. 1985;62(3):234-241.
36. Minto CF, Schnider TW, Short TG, et al. Response surface model for anesthetic drug interactions. *Anesthesiology*. 2000;92(6):1603-1616.
37. Minto C, Vuyk J. Response surface modelling of drug interactions. *Adv Exp Med Biol*. 2003;523:35-43.
38. Vuyk J. Pharmacokinetic and pharmacodynamic interactions between opioids and propofol. *J Clin Anesth*. 1997;9(6 suppl):23S-26S.
39. Vuyk J. Drug interactions in anaesthesia. *Minerva Anesthesiol*. 1999;65(5):215-218.
40. Vuyk J. Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. *Acta Anaesthesiol Belg*. 2001;52(4):445-451.
41. Bouillon TW, Bruhn J, Radulescu L, et al. Pharmacodynamic interaction between propofol and remifentanyl regarding hypnosis, tolerance of laryngoscopy, bispectral index, and electroencephalographic approximate entropy. *Anesthesiology*. 2004;100(6):1353-1372.
42. Manyam SC, Gupta DK, Johnson KB, et al. Opioid-volatile anesthetic synergy: a response surface model with remifentanyl and sevoflurane as prototypes. *Anesthesiology*. 2006;105:267-278.
43. Syroid ND, Agutter J, Drews FA, et al. Development and evaluation of a graphical anesthesia drug display. *Anesthesiology*. 2002;96(3):565-575.
44. Wood M. Plasma binding and limitation of drug access to site of action. *Anesthesiology*. 1991;75(5):721-723.
45. Wood M. Variability of human drug response. *Anesthesiology*. 1989;71(5):631-634.
46. Maitre PO, Aulsems ME, Vozeh S, Stanski DR. Evaluating the accuracy of using population pharmacokinetic data to predict plasma concentrations of alfentanil. *Anesthesiology*. 1988;68(1):59-67.
47. Johnson KB, Syroid ND, Gupta DK, et al. An evaluation of remifentanyl propofol response surfaces for loss of responsiveness, loss of response to surrogates of painful stimuli and laryngoscopy in patients undergoing elective surgery. *Anesth Analg*. 2008;106(2):471-479, table of contents.
48. Johnson KB, Syroid ND, Gupta DK, et al. An evaluation of remifentanyl-sevoflurane response surface models in patients emerging from anesthesia: model improvement using effect-site sevoflurane concentrations. *Anesth Analg*. 2010;111(2):387-394.
49. Syroid ND, Johnson KB, Pace NL, et al. Response surface model predictions of emergence and response to pain in the recovery room: an evaluation of patients emerging from an isoflurane and fentanyl anesthetic. *Anesth Analg*. 2010;111(2):380-386.
50. Schumacher PM, Dossche J, Mortier EP, et al. Response surface modeling of the interaction between propofol and sevoflurane. *Anesthesiology*. 2009. 111(4):790-804.
51. Gin T. Clinical pharmacology on display. *Anesth Analg*. 2010;111(2):256-258.
52. Kennedy RR. Seeing the future of anesthesia drug dosing: moving the art of anesthesia from impressionism to realism. *Anesth Analg*. 2010;111(2):252-255.
53. Short TG. Using response surfaces to expand the utility of MAC. *Anesth Analg*. 2010;111(2):249-251.
54. Struys MM, De Smet T, Mortier EP. Simulated drug administration: an emerging tool for teaching clinical pharmacology during anesthesiology training. *Clin Pharmacol Ther*. 2008;84(1):170-174.
55. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. *JAMA*. 1994;272(3):205-211.
56. Williamson DF, Pamuk ER. The association between weight loss and increased longevity. A review of the evidence. *Ann Intern Med*. 1993;119(7 Pt 2):731-736.
57. Egan TD, Huizinga B, Gupta SK, et al. Remifentanyl pharmacokinetics in obese versus lean patients. *Anesthesiology*. 1998;89(3):562-573.
58. Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics of sufentanil in obese patients. *Anesth Analg*. 1991;73(6):790-793.
59. Shibutani K, Inchiosa MA Jr, Sawada K, Bairamian M. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight ("pharmacokinetic mass"). *Anesthesiology*. 2004;101(3):603-613.
60. Schnider TW, Minto CF, Gambus PL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. *Anesthesiology*. 1998;88(5):1170-1182.
61. Abernethy DR, Greenblatt DJ, Divoll M, et al. Alterations in drug distribution and clearance due to obesity. *J Pharmacol Exp Ther*. 1981;217:681-685.
62. Bouillon T, Shafer SL. Does size matter? *Anesthesiology*. 1998;89(3):557-560.
63. Minto CF, Schnider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanyl. II. Model application. *Anesthesiology*. 1997;86(1):24-33.
64. Fagard R, Staessen J. Relation of cardiac output at rest and during exercise to age in essential hypertension. *Am J Cardiol*. 1991;67(7):585-589.
65. Upton RN, Ludbrook GL, Grant C, Martinez AM. Cardiac output is a determinant of the initial concentrations of

- propofol after short-infusion administration. *Anesth Analg*. 1999;89(3):545-552.
66. Upton RN, Huang YF. Influence of cardiac output, injection time and injection volume on the initial mixing of drugs with venous blood after i.v. bolus administration to sheep. *Br J Anaesth*. 1993;70(3):333-338.
 67. Krejcie TC, Avram MJ. What determines anesthetic induction dose? It's the front-end kinetics, doctor! *Anesth Analg*. 1999;89(3):541-544.
 68. Stanski DR, Maitre PO. Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited. *Anesthesiology*. 1990;72(3):412-422.
 69. Homer TD, Stanski DR. The effect of increasing age on thiopental disposition and anesthetic requirement. *Anesthesiology*. 1985. 62(6):714-724.
 70. Rodeheffer RJ, Gerstenblith G, Becker LC, et al. Exercise cardiac output is maintained with advancing age in healthy human subjects: cardiac dilatation and increased stroke volume compensate for a diminished heart rate. *Circulation*. 1984;69(2):203-213.
 71. Williams TF. Aging or disease? *Clin Pharmacol Ther*. 1987;42(6):663-665.
 72. Avram MJ, Krejcie TC, Henthorn TK. The relationship of age to the pharmacokinetics of early drug distribution: the concurrent disposition of thiopental and indocyanine green. *Anesthesiology*. 1990;72(3):403-411.
 73. Scott JC, Stanski DR. Decreased fentanyl and alfentanil dose requirements with age. A simultaneous pharmacokinetic and pharmacodynamic evaluation. *J Pharmacol Exp Ther*. 1987;240(1):159-166.
 74. Jacobs JR, Reves JG, Marty J, et al. Aging increases pharmacodynamic sensitivity to the hypnotic effects of midazolam. *Anesth Analg*. 1995;80(1):143-148.
 75. Halford F. A critique of intravenous anesthesia in war surgery. *Anesthesiology*. 1943;4:67-69.
 76. De Paep P, Belpaire FM, Rosseel MT, Buylaert WA. The influence of hemorrhagic shock on the pharmacokinetic and the analgesic effect of morphine in the rat. *Fundam Clin Pharmacol*. 1998;12(6):624-630.
 77. Egan TD, Kuramkote S, Gong G, et al. Fentanyl pharmacokinetics in hemorrhagic shock: a porcine model. *Anesthesiology*. 1999;91(1):156-166.
 78. Johnson KB, Kern SE, Hamber EA, et al. Influence of hemorrhagic shock on remifentanyl: a pharmacokinetic and pharmacodynamic analysis. *Anesthesiology*. 2001;94(2):322-332.
 79. Weiskopf RB, Bogetz MS. Haemorrhage decreases the anaesthetic requirement for ketamine and thiopentone in the pig. *Br J Anaesth*. 1985;57(10):1022-1025.
 80. De Paep P, Belpaire FM, Rosseel MT, et al. Influence of hypovolemia on the pharmacokinetics and the electroencephalographic effect of propofol in the rat. *Anesthesiology*. 2000;93(6):1482-1490.
 81. De Paep P, Belpaire FM, Van Hoey G, et al. Influence of hypovolemia on the pharmacokinetics and the electroencephalographic effect of etomidate in the rat. *J Pharmacol Exp Ther*. 1999;290(3):1048-1053.
 82. Johnson KB, Egan TD, Kern SE, et al. The influence of hemorrhagic shock on propofol: a pharmacokinetic and pharmacodynamic analysis. *Anesthesiology*. 2003;99(2):409-420.
 83. Johnson KB, Egan TD, Layman J, et al. The influence of hemorrhagic shock on etomidate: a pharmacokinetic and pharmacodynamic analysis. *Anesth Analg*. 2003;96(5):1360-1368, table of contents.
 84. Adams P, Gelman S, Reves JG, et al. Midazolam pharmacodynamics and pharmacokinetics during acute hypovolemia. *Anesthesiology*. 1985. 63(2):140-146.
 85. Klockowski P, Levy G. Kinetics of drug action in disease states. XXV. Effect of experimental hypovolemia on the pharmacodynamics and pharmacokinetics of desmethyldiazepam. *J Pharmacol Exp Ther*. 1988;245(2):508-512.
 86. Benowitz N, Forsyth RP, Melmon KL, Rowland M. Lidocaine disposition kinetics in monkey and man II. Effect of hemorrhage and sympathomimetic drug administration. *Clin Pharmacol Ther*. 1973;16(1):99-109.
 87. Shafer SL. Shock values. *Anesthesiology*. 2004;101(3):567-568.
 88. Graham MR, Thiessen DB, Mutch WA. Left ventricular systolic and diastolic function is unaltered during propofol infusion in newborn swine. *Anesth Analg*. 1998;86(4):717-723.
 89. Johnson KB, Egan TD, Kern SE, et al. Influence of hemorrhagic shock followed by crystalloid resuscitation on propofol: a pharmacokinetic and pharmacodynamic analysis. *Anesthesiology*. 2004;101(3):647-659.
 90. Hiraoka H, Yamamoto K, Okano N, et al. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. *Clin Pharmacol Ther*. 2004;75(4):324-330.
 91. Swenson JD, Davis JJ, Johnson KB. Postoperative care of the chronic opioid-consuming patient. *Anesthesiol Clin North America*. 2005;23(1):37-48.
 92. Davis JJ, Johnson KB, Egan TD, et al. Preoperative fentanyl infusion with pharmacokinetic simulation for anesthetic and perioperative management of an opioid-tolerant patient. *Anesth Analg*. 2003;97(6):1661-1662.
 93. Davis JJ, Swenson JD, Hall RH, et al. Preoperative "fentanyl challenge" as a tool to estimate postoperative opioid dosing in chronic opioid-consuming patients. *Anesth Analg*. 2005;101(2):389-395; table of contents.
 94. Lemmens HJ, Dyck JB, Shafer SL, Stanski DR. Pharmacokinetic-pharmacodynamic modeling in drug development: application to the investigational opioid trefentanyl. *Clin Pharmacol Ther*. 1994;56(3):261-271.
 95. Scott JC, Cooke JE, Stanski DR. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanyl. *Anesthesiology*. 1991;74(1):34-42.
 96. Peng PW, Sandler AN. A review of the use of fentanyl analgesia in the management of acute pain in adults. *Anesthesiology*. 1999;90(2):576-599.
 97. Gourlay GK, Kowalski SR, Plummer JL, et al. Fentanyl blood concentration-analgesic response relationship in the treatment of postoperative pain. *Anesth Analg*. 1988. 67(4):329-337.
 98. Sheiner LB. Learning versus confirming in clinical drug development. *Clin Pharmacol Ther*. 1997;61(3):275-291.
 99. Shafer SL, Varvel JR, Aziz N, Scott JC. Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. *Anesthesiology*. 1990;73(6):1091-1102.